1. Multi-metabolomics and intestine microbiome analysis: YZC extract ameliorates septic-ALI by modulating intestine microbiota to reduce TMAO/NLRP3 signaling.
- Author
-
Cao X, Zhao M, Wang X, Lin J, Yang M, Zhong L, Liang L, Yue Y, Du J, Li J, Zhou T, Yu J, Liang Y, Shi R, Luo R, Shen X, Chen Y, Wang Y, and Shu Z
- Subjects
- Animals, Male, Mice, Mice, Inbred C57BL, Plant Extracts pharmacology, Disease Models, Animal, Network Pharmacology, Gastrointestinal Microbiome drug effects, NLR Family, Pyrin Domain-Containing 3 Protein metabolism, Signal Transduction drug effects, Sepsis drug therapy, Methylamines metabolism, Acute Lung Injury drug therapy, Acute Lung Injury metabolism, Metabolomics
- Abstract
Background: Sepsis causes inflammation in response to infection, often leading to acute lung injury (ALI). Yazhicao (Commelina communis L., YZC) is widely distributed in the global tropics and has good anti-respiratory inflammatory activity; however, the protection of YZC against septic-ALI has not been established., Purpose: The role of YZC in septic-ALI will be investigated in this study., Methods and Results: In this study, YZC was shown to inhibit excessive inflammation and alleviate septic-ALI. Network pharmacology predicts that Quercetin, Acacetin and Diosmetin have the potential to serve as the pharmacological substance basis of YZC in alleviating septic-ALI. The metabolomics results indicated that YZC could improve the metabolic disorders caused by septic-ALI, which were mostly concerned with energy metabolism and amino acid metabolism, with Trimethylamine (TMA)/Trimethylamine N-oxide (TMAO) being potential small molecule metabolic markers for the clinical diagnosis and treatment of septic-ALI. YZC inhibits the initiation and progression of septic-ALI by controlling the TMA/TMAO metabolites. Our results also suggest that YZC protects the intestinal barrier from damage. Furthermore, our research indicated that YZC reduces TMAO synthesis by inhibiting TMA production through remodeling the intestine microbiota. We investigated the mechanism of YZC-mediated protection against septic-ALI and showed that YZC reduced the expression of proteins associated with NLRP3 inflammatory vesicles in the lung by inhibiting the expression of NF-κB., Conclusion: These results show that YZC inhibits the NF-κB/NLRP3 signaling pathway by regulating metabolic and intestinal flora disorders in septic-ALI mice to reduce TMAO synthesis. This study presents a theoretical groundwork for the advancement of novel medications and clinical use of YZC to enhance septic-ALI and furnishes a theoretical rationale for regulating intestinal microbiota as a therapeutic instrument to treat sepsis and septic-ALI., Competing Interests: Declaration of competing interest This manuscript has not been published or presented elsewhere in part or in entirety and is not under consideration by another journal. We have read and understood your journal's policies, and we believe that neither the manuscript nor the study violates any of these. There are no conflicts of interest to declare., (Copyright © 2024. Published by Elsevier GmbH.)
- Published
- 2024
- Full Text
- View/download PDF